cisplatin + 5-fluorouracil (Shanghai International Medical Center)

This combination chemotherapy regimen consists of cisplatin, a platinum-based alkylating agent, and 5-fluorouracil (5-FU), a pyrimidine analog antimetabolite. It is a standard-of-care backbone for various solid tumors, including advanced gastric cancer. In the context of the Shanghai International Medical Center trial (NCT02862561), it serves as the control arm and the chemotherapy backbone for a combination with Precision Cell Immunotherapy. Cisplatin works by forming intra- and inter-strand DNA cross-links, which inhibit DNA replication and transcription, leading to apoptosis. 5-fluorouracil acts as an antimetabolite that irreversibly inhibits thymidylate synthase, thereby disrupting the synthesis of thymidine monophosphate and subsequently DNA synthesis.

Other names

cisplatin and 5-fluorouracil5-FU + cisplatincisplatin + 5-FU